Partnering with Sanguine
Partnerships to empower people to participate in research
and get the samples needed to propel discovery
Our mission from the conception of Sanguine has been to lower the barrier for people to participate in research and in turn fuel discoveries with these much needed samples. Our direct-to-donor model enables us to interact with our donors, obtain electronic medical records (EMR), recall donors, and get additional information directly from the individuals. Although we have an extensive Donor Network of 70,000+, we continue to add new conditions and with that often rely on partnerships with foundations, advocacy groups, and other non-profit organizations to reach the most eligible participants for the research we support.
The impact of partnering with Sanguine
Fang et al. from Takeda Pharmaceuticals published a paper in PLOS titled “Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations.” The study found that while manual and automated methods yield distinct miRNA profiles, both approaches consistently link these miRNAs to angiogenesis pathways, highlighting their potential as biomarkers for early diagnosis and monitoring of Fabry disease.
This work was made possible by individuals with Fabry disease who donated whole blood samples through Sanguine. The Fabry Support & Information Group (FSIG) played a crucial role in identifying potential donors, resulting in 20 participants contributing samples for this study. Our partnership with FSIG has connected us with highly engaged individuals who have participated in multiple studies since to further our understanding and treatment for Fabry Disease.
